Novel Celecoxib Derivative, RF26, Blocks Colon Cancer Cell Growth by Inhibiting PDE5, Activating cGMP/PKG Signaling, and Suppressing β-catenin-dependent Transcription.

Sara SiglerMohammad Abdel-HalimReem K FathallaLuciana Madeira Da SilvaAdam B KeetonYulia Y MaxuitenkoKristy BerryGang ZhouMatthias EngelAshraf H AbadiGary A Piazza

Published in: Anti-cancer agents in medicinal chemistry (2024)

Further evaluation of RF26 for the prevention or treatment of cancer and studying the role of PDE5 in tumorigenesis are warranted.

Keyphrases

signaling pathway
papillary thyroid
epithelial mesenchymal transition
nitric oxide
cell proliferation
squamous cell
squamous cell carcinoma
combination therapy
lymph node metastasis
smoking cessation